Abstract: An improved optical system for a fluorescent polarization instrument including a low wattage, low intensity focused light source and a polarizer/liquid crystal combination in the excitation path focusing excitation light of alternate planes of perpendicular polarization onto a fluorescent liquid sample. Emitted light from the fluorescent sample is filtered, polarized and focused onto a photomultiplier for processing. A series of non-reflective baffles are placed around the sample to reduce reflections. Monitoring means monitor the excitation light and maintain a substantially constant intensity level focused on the sample. The low wattage, low intensity light source is provided by a 50 watt tungsten halogen projector lamp.

Abstract: Disclosed herein are 1-aminomethyl-phthalans represented by the formula ##STR1## wherein R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.

Abstract: Described are oxazolyl (or thiazolyl) hydrazinoalkyl nitrile compounds of the formula ##STR1## wherein R is hydrogen or loweralkyl, R.sub.1 and R.sub.2 independently of one another denote hydrogen, loweralkyl, or phenyl or naphthyl substituted with halo, loweralkyl or loweralkoxy, X is oxygen or sulfur, n and m are each an integer from 0 to 3 inclusive, or pharmaceutically acceptable salts thereof. The compounds are useful as anti-inflammatory agents.

Abstract: This disclosure relates to a method and reagents for determining ligands in biological fluids such as serum, plasma, spinal fluid, amnionic fluid and urine. This disclosure also relates to a novel class of tracer compounds employed as reagents in fluorescence polarization immunoassays.

Abstract: Disclosed herein are 1-aminoalkyl-3,4-dihydronaphthalenes represented by the formula ##STR1## wherein n is 1 or 2; R, R.sub.1, and R.sub.2 are independently selected from hydrogen, hydroxy, loweralkoxy of 1 to 3 carbon atoms, loweralkenyloxy of 1 to 3 carbon atoms, thiomethyl, halo, or ##STR2## wherein R.sub.5 and R.sub.6 are independently selected from hydrogen, loweracyl of 1 to 4 carbon atoms or sulfonyl of the formula ##STR3## wherein R.sub.7 is loweralkyl of 1 to 4 carbon atoms; or R and R.sub.1, or R.sub.1 and R.sub.2 can be taken together to form a methylenedioxy or ethylenedioxy bridge; with the proviso that at least one of R, R.sub.1 or R.sub.2 must be other than hydrogen; and R.sub.3 and R.sub.4 are independently selected from hydrogen; loweralkyl of 1 to 4 carbon atoms; halo-substituted loweralkyl of 1 to 4 carbon atoms; arylalkyl of the formula ##STR4## wherein m is 0, 1 or 2, p is 0 or 1, R.sub.8 is hydrogen or loweralkyl of 1 to 4 carbon atoms and R.sub.9 and R.sub.

Abstract: The present disclosure relates to a novel class of substituted theophylline salts useful as reagents in an irreversible enzyme inhibitor immunoassay for theophylline. The use of such reagents increases the sensitivity of the theophylline assay.

Abstract: 4-amino-6,7-dimethoxy-2-(4-phenylalkanoylpiperazin-1-yl) quinazolines having .alpha..sub.1 -adrenergic receptor antagonistic activity. These compounds are useful in the treatment of hypertension.

Abstract: Described are compounds of the formula ##STR1## wherein R is hydrogen or loweralkyl; R.sub.1 is --OR.sub.2 or --NR.sub.2 R.sub.3 wherein R.sub.2 and R.sub.3 independently of one another denote hydrogen or loweralkyl; n is 0 or 1; R.sub.4 and R.sub.5 independently of one another denote loweralkyl or together form a 5 or 6 membered cycloalkyl substituted by hydrogen or loweralkyl, and together with the nitrogen atom, form a ring; and pharmaceutically acceptable salts thereof and their use as anticonvulsant agents in a method of controlling convulsions or seizures.

Abstract: Disclosed is a synergistic catalytic combination of 1,2-dimethylimidazole with tris(3-dimethylaminopropyl)amine and a salt of 1,8-diazabicyclo(5,4,0)undecene-7. The combination catalyst is useful in polyurethane systems such as elastomers, microcellular, rigid, semirigid, and flexible foams, such as integral skin semiflexible foams used in the manufacture of steering wheels.

Abstract: New ditertiary aminoalcohols are useful as catalysts in the preparation of polyurethane foams. The new catalysts are particularly stable in the presence of polyols and other components often used in the conjunction with such polyols.

Abstract: Disclosed herein are fortimicin derivatives represented by the formula: ##STR1## wherein R is hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, loweracyl, aminoloweracyl, diaminoloweracyl, hydroxyloweracyl, N-loweralkylaminoloweracyl, N,N-diloweralkylaminoloweracyl, or aminohydroxyloweracyl, and the pharmaceutically acceptable salts thereof. Also disclosed are intermediates useful in the preparation of these compounds and compositions of these compounds together with a pharmaceutically acceptable carrier and/or diluent.

Abstract: Disclosed herein are fortimicin derivatives represented by the formula: ##STR1## wherein R.sub.z is a monocyclicaryloxycarbonyl amine protecting group, or is loweralkyl, hydroxyloweralkyl, loweracyl, hydroxyloweracyl, or a monocyclicaryloxycarbonyl-protected aminoloweralkyl, diaminoloweralkyl, N-loweralkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, aminohydroxyloweralkyl, N-loweralkylaminohydroxy-loweralkyl, N,N-diloweralkylaminohydroxyloweralkyl, aminoloweracyl, diaminoloweracyl, N-loweralkylaminoloweracyl, N,N-diloweralkylaminoloweracyl, or aminohydroxyloweracyl; R.sub.1 is hydroxy or loweracyloxy; R.sub.2 is hydrogen, hydroxy or --OR.sub.4, wherein R.sub.4 is tert-butyldimethylsilyl or thiocarbonylimidazoyl; or R.sub.1 and R.sub.2 can be taken together to form ##STR2## wherein R.sub.5 and R.sub.6 are loweralkyl; R.sub.3 is hydroxy or loweracyloxy; and z is a monocyclicaryloxycarbonyl amine protecting group. The compounds are useful as intermediates in the preparation of 3-demethoxyfortimicins.

Abstract: Polyurethane foams with excellent physical properties can be obtained by using a partial salt between N,N-dimethylaminopropane-1,3-diamine (DMAPA) and a branched octanoic acid.

Abstract: Polyurethane foams with excellent physical properties can be obtained by using a partial salt between N,N-dimethylaminopropane-1,3-diamine (DMAPA) and phenol.

Abstract: Polyurethane foams with excellent physical properties can be obtained by using a partial salt between N,N-dimethylaminopropane-1,3-diamine (DMAPA) and a branched octanoic acid.

Abstract: An improved method of producing 2-epi-fortimicin A directly from fortimicin A by protecting the amine functions of fortimicin A, converting the N-protected fortimicin A to an intermediate of the formula: ##STR1## wherein L is a leaving group and Z is an amine-protecting group, reacting the intermediate (I) with a loweralkyl metal halide in N,N-dimethylformamide to form N-protected-2-epi-fortimicin A, and then hydrogenating the N-protected-2-epi-fortimicin A to obtain 2-epi-fortimicin A.

Abstract: Described are compounds of the formula ##STR1## wherein R.sub.2 -R.sub.8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR2## with the proviso that at least one but no more than one of the substituents R.sub.2 -R.sub.8 is ##STR3## and with the further provisos that at least four of the substituents R.sub.2 -R.sub.8 are hydrogen and R.sub.2 cannot be ##STR4## when R.sub.3 -R.sub.8 are hydrogen, and pharmaceutically acceptable salts thereof.The compounds are effective as antiinflammatory and antiasthma agents.

Abstract: New .beta.-lactams of the general structure: ##STR1## wherein X=O or S; R represents H, loweralkyl, acyl, aryl, or arylloweralkyl; R' is hydrogen, loweralkoxy, loweralkoxyalkyl, loweralkyl, phenylthio or loweralkylmercapto; R" is hydrogen or loweralkyl; and the broken line represents an optional double bond, and certain esters thereof. All compounds are effective antibacterials.

Abstract: New .beta.-lactams of the general structure: ##STR1## wherein R represents H or an acyl moiety known from the penicillin or cephalosporin art, R' is hydrogen, loweralkoxy, loweralkoxyalkyl, loweralkyl, phenylthio or loweralkylmercapto R" is loweralkyl, the broken line represents an optional double bond, and acyloxymethyl esters thereof. All compounds are effective antibacterials.

Abstract: A 1,2-modified fortimicin A or B represented by the formulae I, II and III: ##STR1## wherein R is hydrogen or loweralkyl; and R.sub.1 is selected from the group consisting of hydrogen, loweralkyl, aminoloweralkyl, diaminoloweralkyl, N-lower-alkylaminoloweralkyl, N,N-diloweralkylaminoloweralkyl, hydroxyloweralkyl, amino hydroxyloweralkyl, N-loweralkylaminohydroxyloweralkyl, N-N-diloweralkylaminohydroxyloweralkyl, acyl, aminoacyl, hydroxy-substituted aminoacyl, diaminoacyl, hydroxyacyl, hydroxy-substituted diaminoacyl, N-loweralkylaminoacyl, N, N-diloweralkylaminoacyl, hydroxysubstituted-N-loweralkylaminoacyl and hydroxy-substituted-N, N-diloweralkylaminoacyl, and the pharmaceutically acceptable salts thereof. The compounds are broad spectrum antibiotics.